Microbot Medical (MBOT) announced that its LIBERTY System, the first FDA cleared single-use, remotely operated robotic system for peripheral endovascular procedures, is now commercially available in the U.S. The Limited Market Release, LMR, will introduce LIBERTY to selected high procedure volume regions where the Company already experienced preliminary demand for LIBERTY. The LMR will focus on collecting real-world insights from potential high-volume users to guide responsible growth and ensure consistent quality and performance, leading to the expected Full Market Release, FMR, during the Society of Interventional Radiology, the largest U.S. medical conference for Interventional Radiology, in April 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBOT:
- Microbot Medical Showcases LIBERTY® System Post-FDA Clearance
- Microbot Medical to commercially debut LIBERTY System at Symposium
- Microbot Medical Partners for LIBERTY System Launch
- Microbot Medical partners with 3PL company to commercialize LIBERTY System
- Microbot Medical files to sell 900,153 shares of common stock for holders